Nov, 27 2018 18:02 JST

Source: Eisai

Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium


TOKYO, Nov, 27 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 4 through 8, 2018, in San Antonio, Texas in the United States.

A total of four presentations will be given at this year's SABCS, including the results of biomarker research from a Phase II clinical study evaluating eribulin in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (product name: KEYTRUDA) for triple-negative metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.


Latest Release

More Latest Release >>